Table 3.
Association Between Each Candidate Marker Individually When Modeled as a Categorical Variable and the Odds of Cardiovascular Death or HF at 30 Days After Multivariable Adjustment
| Biomarker | OR (95% CI) Adjusted for Clinical Factors Modeled Applying a Dichotomous Threshold | P Value | |
|---|---|---|---|
| Myocardial stress/structural changes | NT‐proBNP (n=1142) | 2.54 (1.47–4.37) | 0.001 |
| MR‐proANP (n=1027) | 2.18 (1.27–3.76) | 0.005 | |
| ST2 (n=1133) | 2.88 (1.72–4.81) | <0.001 | |
| Galectin‐3 (n=943) | 1.74 (0.96–3.16) | 0.07 | |
| MR‐proADM (n=1032) | 1.07 (0.61–1.87) | 0.82 | |
| Copeptin (n=1031) | 1.12 (0.63–1.99) | 0.71 | |
| Myonecrosis (n=1142) | Troponin T (T1–T2)a | 2.40 (1.22–4.71) | 0.01 |
| Troponin T (T3)a | 4.37 (2.15–8.89) | <0.001 | |
| Inflammation | MPO (n=952) | 2.75 (1.20–6.27) | 0.02 |
| hsCRP (n=1140) | 1.96 (1.17–3.30) | 0.01 | |
| PAPP‐A (n=794) | 3.04 (1.17–7.88) | 0.02 | |
| GDF‐15 (n=1019) | 0.81 (0.41–1.60) | 0.54 |
Multivariable model included age, sex, past HF, diabetes mellitus, past MI, systolic blood pressure, heart rate, Killip class II to IV, type of lytic, anterior STEMI, creatinine clearance <60 mL/min, time to lytic, treatment arm. Gal‐3 indicates galectin‐3; GDF‐15, growth‐differentiation factor‐15; HF, heart failure; hsCRP, high‐sensitivity C‐reactive protein; MI, myocardial infarction; MPO, myeloperoxidase; MR‐proADM, midregional proadrenomedullin; MR‐proANP, midregional proatrial natriuretic peptide; NT‐proBNP, NT‐pro B‐type natriuretic peptide; OR, odds ratio; PAPP‐A, pregnancy‐associated plasma protein A; ST2, suppression of tumorigenicity 2; STEMI, ST‐elevation myocardial infarction.
For categorical analysis, troponin T was coded as 3‐way variable with undetectable troponin T as referent and detectable troponin T modeled by tertile (T).